{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoLTszoUKDA","founded_year":1897,"lastupdate":"2023-02-26T00:00:00.000Z","update_date":"2023-02-26T00:00:00.000Z","lastModified":"Apr 30, 2023","confidence_score":68,"active":1,"confidence_score_reason":"product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed","urlname":"lonza","minimal_profile":null,"status":"Public","fullstatus":"Public on SIX on May, 1986;","acquired":0,"description_edited":1,"tag_line_edited":1,"phone":"","registrar":"","biverification":"Jenny Sotnik-Talisman","recentupdates":[{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:19:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 16:11:21.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:13:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:59:14.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:17:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:46:56.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:08:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:21:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:57:38.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:57.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:31:35.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:46:10.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:08:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:21:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 04:55:43.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:19:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:16:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:44.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:46:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:46:10.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-03-20 06:25:56.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:07:25.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-02-13 06:50:22.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:47:34.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 07:56:46.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:10:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:10:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:10:17.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2017-10-17 12:34:17.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2017-10-17 12:34:17.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2017-10-17 12:34:17.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2017-10-17 12:35:32.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-02-02 08:49:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:20:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:20:20.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:09:25.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:09:25.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:23:16.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:20:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:11:05.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:23:04.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:10:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:08:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:20:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:27:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:27:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:10:47.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-10-10 08:21:52.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-11-20 13:31:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:57:13.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:09:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:09:08.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:52:06.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:55:12.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:07:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:07:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:44:19.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:44:19.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:44:19.000000","last_name":"McCandless","first_name":"Katie"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:07:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:59:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:59:09.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:09:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:55:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 08:55:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-09-26 09:09:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-31 11:55:51.000000","last_name":"McCandless","first_name":"Katie"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:18:32.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:08:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2022-11-04 18:46:10.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:21:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:21:58.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:18:32.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:21:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:13:45.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:32:09.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 07:56:46.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:20:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:40:52.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-26 18:08:22.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2019-09-26T00:00:00.000Z","crunchbaseid":"lonza-group","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2017-10-10T00:00:00.000Z","lastupdatedate":"2023-02-26","hide_reason":null,"hide_reason_data":null,"logokey":"$LRRR62m9mXxbp6aW6USoVDrqQsz4UyK0NoNLTaeVjy1331Rxy05qiL","name":"Lonza","israeliacquisitions":0,"forbesranking":791,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":[""],"country":"Switzerland","inisraelsince":"4/2017","inisraelsincemonth":"4","isisraeli":0,"marketcapital":48281382625,"marketcapitaldate":"2025-11-01T14:07:49.000Z","oneliner":"Pharmaceuticals","website":"http://www.lonza.com","employees":"11-50","employees_exact":21,"employees_overall":"10,001-50,000","employees_overall_exact":18430,"sociallinks":{"twitter":"https://twitter.com/LonzaGroup","youtube":"https://www.youtube.com/user/LonzaGroup","facebook":"https://www.facebook.com/LonzaGroupAG","linkedin":"https://www.linkedin.com/company/7462","instagram":""},"social":["https://www.linkedin.com/company/7462","https://www.youtube.com/user/LonzaGroup","https://twitter.com/LonzaGroup","https://www.facebook.com/LonzaGroupAG"],"flattenedsociallinks":"https://www.linkedin.com/company/7462|https://www.youtube.com/user/LonzaGroup|https://twitter.com/LonzaGroup|https://www.facebook.com/LonzaGroupAG","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Lonza Group offers products and services including custom development and manufacturing of active pharmaceutical ingredients and innovative dosage forms for the pharmaceutical and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients, the company provides agricultural products, advanced coatings and composites, and microbial control solutions that combat dangerous viruses, bacteria, and other pathogens.\n\nLonza opened a collaborative innovation center in Israel in 2017, which focuses on pharmaceutical and biotech research. The center serves as the company's link to local collaborations and partnerships with academic institutes, hospitals, and startups. In addition, Lonza has R&D activities in Israel, including a partnership with Sheba Medical Center to develop personalized cancer therapies. The company also collaborates with Israeli universities and research institutions to advance research in areas such as cell therapy, gene therapy, and vaccine development. Lonza's Technology & Innovation Center in Haifa, Israel, is focused on developing innovative solutions in areas such as drug delivery, bioconjugation, and bioanalytics. Overall, Lonza considers Israel to be an important location for its R&D activities and is committed to further expanding its presence in the country.","founded":"1897","team":[{"name":"Frida Grynspan","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IrC2awKDA","bounced":false,"claimed":0,"founder":0,"urlname":"frida-grynspan-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgivewnQgM","position":"Head of Lonza Collaborative Innovation Center","last_name":"Grynspan","claimtoken":"24d8513a398b4906573a5b3ca4230e1c8af1a4d2e0629b43e42f794af470ddb6","first_name":"Frida","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/frida-grynspan-0123a17/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"FG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Pnina Weitz","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IqwjsULDA","bounced":false,"claimed":0,"founder":0,"urlname":"pnina-weitz","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg8qmg4goM","position":"Head of Strategic Relationship Management ","last_name":"Weitz","claimtoken":"xjg9LqlD7bS10aRxA29eIijkw9YPhqv6vjnkL3Vhe6HitdaDbSnoq2","first_name":"Pnina","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/pnina-weitz-80920789/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-02-26 18:10:20.000000","initials":"PW","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Vitaly Levin","email":"","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4NLwpKQJDA","bounced":false,"claimed":0,"founder":0,"urlname":"vitaly-levin","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg0qP_rwsM","position":"CIC Site Operation Manager","last_name":"Levin","claimtoken":"065984ab5f68913884d510585c47f0c96b728d07222aea40dacbd5a68fc572a4","first_name":"Vitaly","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/vitaly-levin-893b2b87/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"VL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Iris  Geffen Gloor","email":"","phone":"","gender":"Female","userid":"uWX712mXjQXHkWyTT7aCf6dNUPpoo1KxhWzwOQVX75cOnWNHJbDZsO","bounced":false,"claimed":null,"founder":0,"urlname":"iris-geffen-gloor","visible":1,"memberid":"ldzVUpWXLw3qC7x1ORljYAshRZS14VAHU2097XFHL5UMkEXUqGip9f","position":"Director, External Innovations, Biologics R&D","last_name":"Geffen Gloor","claimtoken":null,"first_name":"Iris ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/iris-geffen-gloor-0631b1a/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"IG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"NOGA Therapeutics","hidden":false,"raised":"$1M","founded":"2020","fullurl":"/company_page/noga-therapeutics","logokey":"$dbv9LSvc2PaWmRzhJSq9lgprfsWQRthrTDwcD8bCrbK4uV8qMsAALT.png","urlname":"noga-therapeutics","employees":"1-10","company_id":"p6KW2wutRzDcrbRzF6dcmYU1rrfH4sYzQnhR18rBWHKyK7TJy16fBK","description":"Gene Therapies for Severe and Chronic Illnesses","fundingstage":"Seed","businessmodel":"B2B","raisedNumber":1000000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$dbv9LSvc2PaWmRzhJSq9lgprfsWQRthrTDwcD8bCrbK4uV8qMsAALT.png","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"1bf22920-0ba4-48ef-aee5-9f793edac532","city":"Haifa","type":["R&D "," Innovation Center"],"address":"Netiv HaOr, Haifa, Israel","placeid":null,"notactive":0,"openeddate":"2017-04-01","registrarid":"515636066","firstrdcenter":0,"registrarname":"Lonza Israel Ltd"}],"officesabroad":null},"headquarter_address":"Basel, Switzerland","news":[{"id":"fsVkwAG9EBmPHCgUCgWFwUTXYQEF7zlgboQP9o8FCgm7jF2pWnZrUF","date":"Aug 12, 2021","link":"https://www.biopharminternational.com/view/lonza-and-sheba-medical-center-demonstrate-successful-cell-therapy-results-with-cocoon-automated-platform","source":"www.biopharminternational.com","visible":1,"analysis":{"tags":"CAR-T cell therapy","company":"Lonza","layoffs":null,"summary":"Lonza and Sheba Medical Center have successfully dosed four patients with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon automated manufacturing platform. Three out of four patients showed complete responses. The Cocoon platform is flexible and capable of manufacturing immunotherapies for personalized point-of-contact treatment. Lonza and Sheba Medical Center plan to dose additional patients using the Cocoon platform. The collaboration between Lonza and Sheba Medical Center aims to revolutionize the production of patient-scale cell therapy and make it available to more patients in need.","partners":"Sheba Medical Center","customers":null,"investors":null,"confidence":9,"key_topics":["CD19 autologous CAR-T cell therapy","Lonzas Cocoon automated manufacturing platform","Successful dosing of patients","Collaboration with Sheba Medical Center","Advantages of the Cocoon platform"],"date_of_event":"2021-08-12","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"OmRin7QUicegtR0kVIVGt8AP3CCPBKu35Vkc85pfSYKk7SJobacCWR","news_summary":"Lonza and Sheba Medical Center Demonstrate Successful Cell Therapy Results with Cocoon Automated Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2317f198-a07d-4e14-b485-ea39fd408eda","date":"Nov 20, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3750251,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"collaborative innovation center","company":"Lonza","layoffs":null,"summary":"Lonza has opened its collaborative innovation center in Israel, which will serve as the companys link to local collaborations and partnerships with academic institutes, hospitals, and startups. The center focuses on three main research areas: expression systems and synthetic biology, cell and gene therapies, and data acquisition and analytics. It is headed by biochemist Frida Grynspan-Gotlieb.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["collaborative innovation center","Israel","research areas","partnerships","biochemist"],"date_of_event":"2017-10-01","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7g4SRgII5B6Yt04DWDLpgZZTDOoUe0BbhYHBzuuVCpvt5zF4bz0MGH","news_summary":"Lonza Opens Israeli Innovation Center","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b1078a03-96ee-48d7-9edb-b988d61b8652","date":"Oct 10, 2017","link":"https://www.technologynetworks.com/tn/news/lonza-announces-formation-of-new-center-in-israel-293014","source":"www.technologynetworks.com","visible":1,"analysis":{"tags":"Collaborative Innovation Center","company":"Lonza","layoffs":null,"summary":"Lonza has announced the establishment of the Lonza Collaborative Innovation Center (CIC) in Israel. The CIC aims to accelerate R&D projects and tap into transformative biological and manufacturing capabilities. Lonza plans to hire 15-20 staff members in 2018 to leverage Israels scientific strengths. The company has already signed memorandums of understanding and conducted talent scouting at various Israeli institutions. Eytan Abraham and Roee Atlas will be responsible for setting up and managing the center, respectively.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Lonza Collaborative Innovation Center","R&D projects","biological and manufacturing capabilities","partnerships","talent scouting"],"date_of_event":"Q4 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TsquUeuxgUGssALM83aCCkQDREX2SPjLb4cWn3e4STsI939evclYil","news_summary":"Lonza Announces Formation of New Center in Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"joPHKearkoMCCMQ4NitNHZNpHVo278uZhXCXisvTHJrfpuwUFDY1ZT","hub":null,"date":"1986-05-01","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"LONN","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"SIX","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIkJbHCQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$8SB85SISCfwYkSyUwLjTE2ozNx7CLkx63mQwuJlCCcFmIUyR7m5z8P","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["drug-delivery","pharmaceuticals","biotechnology","innovation-center"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"10,001-50,000","fundingtype":"Multinational","parsedName":"Lonza","logourl":"https://storage.googleapis.com/clean-finder-353810/$LRRR62m9mXxbp6aW6USoVDrqQsz4UyK0NoNLTaeVjy1331Rxy05qiL","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$LRRR62m9mXxbp6aW6USoVDrqQsz4UyK0NoNLTaeVjy1331Rxy05qiL","teamMembersNumber":4,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}